OUR DERMATOLOGY STORY

IN PURSUIT OF BETTER DERMATOLOGY AND BETTER LIVES

Our products are designed to address the essential areas of dermatology.

We launched Cassiopea with a deliberate goal in mind: find a new way to treat acne. We are building our company on this foundation, targeting unmet needs and opportunities for Cassiopea to advance the practice of dermatology.

THE SKINCARE STORY

ACNE

Acne, a chronic inflammatory skin disease, is one of the most common reasons patients visit a dermatologist. The major product classes predominantly used to treat acne have been available for nearly 40 years, and we believe that recent growth in this market has been significantly limited by a lack of innovation in new product development.

The story in numbers:
50 million
acne sufferers
in the US each year1
>5.1 million
people actively seeking
treatment for acne1
6.5%
projected market
growth by 20242
Nearly 40 years
since a novel therapeutic acne innovation was introduced3
ANDROGENETIC ALOPECIA (AGA)

AGA is the most common cause of hair loss,4 affecting a large percentage of both men and women. The prescription treatment options are limited, yet there is a growing demand for choices as many patients choose OTC remedies.

AGA is another major contributor to confidence loss that deserves a new treatment. Many patients remain untreated and continue to suffer in silence.

The story in numbers:
1
prescription drug
available in current
US market
50%
of men
experience AGA4
50%
of women
experience AGA5
GENITAL WARTS

Genital warts are a symptom of the highly contagious sexually transmitted disease, human papillomavirus (HPV). They are spread through direct skin-to-skin contact, often by those who do not develop genital warts and therefore do not know they are infected. Today, topical treatments are common, but many require multiple applications and can be ineffective—recurrence is frequent.

Genital warts can adversely affect sexual health and wellness. Finding effective treatment is imperative.

79 million
people in the US
with HPV in 20136
360,000
people develop
anogenital warts
every year7
80%
of sexually active people
will contract HPV in their lives8

References: 1. American Academy of Dermatology (AAD). Skin conditions by the numbers. AAD website. https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed July 24, 2019. 2. Global Market Insights (GMI). Acne medication market size by formulation (topical, oral), by product (retinoids, antibiotics, salicylic acid, benzoyl peroxide, azelaic acid), by type (prescription, OTC), by age group (0-10 years, 11-16 years, 17-25 years, 26-40 years, 41-60 years, 61-80 years, 80+ years), industry analysis report, regional outlook (U.S., Canada, Germany, UK, Italy, France, Spain, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia), application potential, competitive market share & forecast, 2018-2024. GMI website. Accessed July 25, 2019. 3. Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162-169. 4. Qi J, Garza LA. An overview of alopecias. Cold Spring Harb Perspect Med. 2014;4(3):1. 5. Ho CH, Zito PM. Androgenetic alopecia. Treasure Island, FL; StatPearls Publishing; 2019. 6. Centers for Disease Control and Prevention (CDC). Genital HPV infection – fact sheet. CDC website. https://www.cdc.gov/std/hpv/stdfact-hpv.htm. Accessed July 23, 2019. 7. Anal Cancer Foundation (ACF). About HPV/treatment/warts. ACF website. https://www.analcancerfoundation.org/about-hpv/treatment/warts/. Accessed July 24, 2019. 8. American Sexual Health Association (ASHA). Fast facts. ASHA website. http://www.ashasexualhealth.org/stdsstis/hpv/fast-facts/. Accessed July 23, 2019.

LATEST NEWS

November 13, 2019
chevron right icon

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

November 8, 2019
chevron right icon

Cassiopea Announces FDA Acceptance of its New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

August 20, 2019
chevron right icon

Cassiopea Announces FDA Submission of New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.

Winlevi is under investigation in the United States for the treatment of acne, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone cream 1% is not FDA-approved.